Nanomedicine-based immunotherapy for central nervous system disorders

Sumaira Hanif, Pir Muhammad, Rose Chesworth, Fawad Ur Rehman, Rong-jun Qian, Meng Zheng, Bingyang Shi*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    34 Citations (Scopus)


    Central nervous system (CNS) disorders represent a broad spectrum of brain ailments with short- and long-term disabilities, and nanomedicine-based approaches provide a new therapeutic approach to treating CNS disorders. A variety of potential drugs have been discovered to treat several neuronal disorders; however, their therapeutic success can be limited by the presence of the blood-brain barrier (BBB). Furthermore, unique immune functions within the CNS provide novel target mechanisms for the amelioration of CNS diseases. Recently, various therapeutic approaches have been applied to fight brain-related disorders, with moderate outcomes. Among the various therapeutic strategies, nanomedicine-based immunotherapeutic systems represent a new era that can deliver useful cargo with promising pharmacokinetics. These approaches exploit the molecular and cellular targeting of CNS disorders for enhanced safety, efficacy, and specificity. In this review, we focus on the efficacy of nanomedicines that utilize immunotherapy to combat CNS disorders. Furthermore, we detailed summarize nanomedicine-based pathways for CNS ailments that aim to deliver drugs across the BBB by mimicking innate immune actions.
    Original languageEnglish
    Pages (from-to)936-953
    Number of pages18
    JournalActa Pharmacologica Sinica
    Issue number7
    Early online date28 May 2020
    Publication statusPublished - Jul 2020


    • blood–brain barrier
    • central nervous system disorders
    • immunotherapy
    • nanomedicine


    Dive into the research topics of 'Nanomedicine-based immunotherapy for central nervous system disorders'. Together they form a unique fingerprint.

    Cite this